eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

Real-world data in NVAF

ELIQUIS (apixaban): favourable efficacy and major bleeding outcomes vs. warfarin, demonstrated in randomised controlled trials,1 are now reflected by real-world experience in the USA2

ELIQUIS is the only factor Xa inhibitor that has demonstrated significant risk reduction in stroke / systemic embolism with significantly less major bleeding vs. warfarin.1


ELIQUIS efficacy and safety in patients with NVAF have been demonstrated in clinical trials3

ELIQUIS 5 mg BD: simple dosing for stroke prevention in NVAF, with or without food

View the latest AF treatment guidelines

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

AF = Atrial Fibrillation   
ARR = Absolute Risk Reduction   
BD = Twice Daily   
CI = Confidence Interval   
HR = Hazard Ratio   
ICD-9 = The International Classification of Diseases, Ninth Revision   
NOAC = Non-vitamin K antagonist Oral Anticoagulant   
NVAF = Non-Valvular Atrial Fibrillation   
OD = Once Daily   
RCT = Randomised Controlled Trial   
RRR = Relative Risk Reduction

# The analysis included outcomes that occurred on treatment, defined as the time after the first eligible prescription fill until the end of enrolment in health plans, the end of the study period (30 June 2015), discontinuation of treatment, or switching to another oral anticoagulant.2

The analysis included outcomes that occurred on treatment and were identified using ICD-9 codes in the primary or secondary diagnosis positions of inpatient claims.2


  1. Granger CB et al. N Eng J Med 2011; 365: 981–992.
  2. Yao X et al. J Am Heart Assoc 2016; 5: e003725.
  3. ELIQUIS® (apixaban) Summary of Product Characteristics.